ArticleScientific reports2015
Convertible MRI contrast: Sensing the delivery and release of anti-glioma nano-drugs.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Exposed Phosphatidylserine as a Biomarker for Clear Identification of Breast Cancer Brain Metastases in Mouse Models.Cancers · 2024Article
- Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives.CNS neuroscience & therapeutics · 2024Review
- Dysregulation of cellular membrane homeostasis as a crucial modulator of cancer risk.The FEBS journal · 2024Review
- Transfer Learning Approach to Vascular Permeability Changes in Brain Metastasis Post-Whole-Brain Radiotherapy.Cancers · 2023Article
- Aerosolized immunotherapeutic nanoparticle inhalation potentiates PD-L1 blockade for locally advanced lung cancer.Nano research · 2023Article
- Cooperative coordination-mediated multi-component self-assembly of "all-in-one" nanospike theranostic nano-platform for MRI-guided synergistic therapy against breast cancer.Acta pharmaceutica Sinica. B · 2022Article
- Deep learning quantification of vascular pharmacokinetic parameters in mouse brain tumor models.Frontiers in bioscience (Landmark edition) · 2022Article
- Modernistic and Emerging Developments of Nanotechnology in Glioblastoma-Targeted Theranostic Applications.International journal of molecular sciences · 2022Review
- Manganese in Diagnostics: A Preformulatory Study.Pharmaceutics · 2022Article
- Current Status of Brain Tumor in the Kingdom of Saudi Arabia and Application of Nanobiotechnology for Its Treatment: A Comprehensive Review.Life (Basel, Switzerland) · 2021Review
- Review of Contemporary Self-Assembled Systems for the Controlled Delivery of Therapeutics in Medicine.Nanomaterials (Basel, Switzerland) · 2021Review
- Liposome-Coated Arsenic-Manganese Complex for Magnetic Resonance Imaging-Guided Synergistic Therapy Against Carcinoma.International journal of nanomedicine · 2021Article
- Targeted cancer cell delivery of arsenate as a reductively activated prodrug.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2020Article
- Nano-Therapies for Glioblastoma Treatment.Cancers · 2020Review
- An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases.Nature communications · 2019Article
- Stimulus-responsive liposomes as smart nanoplatforms for drug delivery applications.Nanotechnology reviews · 2018Article
- Intrinsic and Stable Conjugation of Thiolated Mesoporous Silica Nanoparticles with Radioarsenic.ACS applied materials & interfaces · 2017Article
- Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers.Journal of biomedical research · 2017Article
- Phosphatidylserine-Targeted Nanotheranostics for Brain Tumor Imaging and Therapeutic Potential.Molecular imaging · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
There is considerable interest in developing nanohybrids of imaging contrast agents and drugs for image-guided drug delivery. We have developed a strategy of utilizing manganese (Mn) to enhance the nano-encapsulation of arsenic trioxide (ATO). Formation of arsenite (As(3+))-Mn precipitates in liposomes generates magnetic susceptibility effects, reflected as dark contrast on T2-weighted MRI. Intriguingly, following cell uptake, the As-Mn complex decomposes in response to low pH in endosome-lysosome releasing ionic As(3+), the active form of ATO, and Mn(2+), the T1 contrast agent that gives a bright signal. Glioblastoma (GBM) is well known for its high resistance to chemotherapy, e.g., temozolomide (TMZ). Building upon the previously established phosphatidylserine (PS)-targeted nanoplatform that has excellent GBM-targeting specificity, we now demonstrate the effectiveness of the targeted nanoformulated ATO for treating TMZ-resistant GBM cells and the ability of the convertible Mn contrast as a surrogate revealing the delivery and release of ATO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.